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Abstract
KIAA1549-BRAF is the most frequently identified genetic mutation in sporadic pilocytic astrocytoma (PA), creating a
fusion BRAF (f-BRAF) protein with increased BRAF activity. Fusion-BRAF-expressing neural stem cells (NSCs) exhibit
increased cell growth and can generate glioma-like lesions following injection into the cerebella of naïvemice. Increased
Iba1+ monocyte (microglia) infiltration is associated with murine f-BRAF-expressing NSC-induced glioma-like lesion
formation, suggesting that f-BRAF-expressing NSCs attract microglia to establish a microenvironment supportive of
tumorigenesis. Herein, we identify Ccl2 as the chemokine produced by f-BRAF-expressing NSCs, which is critical for
creating apermissive stroma for gliomagenesis. In addition, f-BRAF regulation of Ccl2 production operates in anERK- and
NFκB-dependent manner in cerebellar NSCs. Finally, Ccr2-mediated microglia recruitment is required for glioma-like
lesion formation in vivo, as tumor do not form in Ccr2-deficient mice following f-BRAF-expressing NSC injection.
Collectively, these results demonstrate that f-BRAF expression creates a supportive tumor microenvironment through
NFκB-mediated Ccl2 production and microglia recruitment.
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Introduction
Low-grade gliomas (LGGs) represent the most common central
nervous system (CNS) tumor occurring in children, with pilocytic
astrocytoma (PAs) being the most frequently encountered benign
neoplasm in this age group [1]. Themajority of pediatric LGGs are caused
by tandem duplications involving the BRAF gene (e.g.,KIAA1549:BRAF
rearrangement), which typifies sporadic PAs arising in the cerebellum
[2–4]. Based on these observations, we previously demonstrated that
ectopicKIAA1549:BRAF expression in mouse cerebellar neural stem cells
(NSCs) is sufficient to generate glioma-like lesions following implantation
in the naïve murine cerebellum [5]. In addition, increased KIAA1549:
BRAF-driven NSC proliferation is mediated through hyperactivation of
the MEK/ERK signaling pathway [5].
Similar to low-grade gliomas arising in children with the Neurofibro-
matosis type 1 (NF1) cancer predisposition syndrome, these glial tumors
are highly dependent on their local microenvironment, and in
experimental model systems, are controlled by non-neoplastic stromal
cells. Prior studies using Nf1 genetically engineered mouse strains have
revealed that brainmonocytes (microglia) are the driving stromal cell type
in these tumors, such that their genetic or pharmacologic inhibition
attenuates tumor formation and growth [6–8]. Importantly, monocytes
can comprise as many as 30–50% of the total number of cells in
PAs [9,10]. The presence of these monocytes suggests that the
recruitment and activation of microglia and macrophages represent key
steps in glioma formation and maintenance.
In order to define the role of microglia in sporadic KIAA1549:
BRAF (f-BRAF)-driven low-grade glioma, we leveraged converging
in vitro and in vivo approaches to demonstrate that KIAA1549:BRAF
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positively regulates cerebellar NSC Ccl2 expression through ERK-
dependent NFκB activation. The importance of Ccl2 to tumorigen-
esis was further underscored by the failure of low-grade glioma-like
lesions to form following the implantation of f-BRAF-expressing
NSCs into Ccr2−/− mice.
Materials and Methods
Mice
The KIAA1549:BRAF conditional transgenic mouse strain were
generated as previously described [11]. Ccr2+/RFP (Keiko Hirose,
Washington University) were intercrossed to generate Ccr2−/−
(Ccr2RFP/Ccr2RFP) mice. All mice were maintained on a C57BL/6
background, and used in accordance with an approved Animal
Studies protocol at Washington University.
Primary NSC Isolation and Culture
Cerebellar hemispheres were micro-dissected from the brains of
postnatal day 2–3 (PN2–3) conditional f-BRAF (Lox-STOP-Lox-
KIAA1549:BRAF transgenic mice [11]) pups to establish primary
neural stem cell (NSC) cultures [12]. Control and f-BRAF-expressing
NSCs were generated following infection with Adenovirus type 5 (Ad5)
containing β-galactosidase (Ad5-LacZ) or Cre recombinase (Ad5-Cre)
(University of Iowa Gene Transfer Vector Core, Iowa City). Ectopic f-
BRAF expression in NSCs was also generated through retrovirus
infection (Peter Collins, University of Cambridge). The constructs used
for retroviral infection were pBABE-puro KIAA1549:BRAF and
pBABE-puro. f-BRAF-expressing cells were confirmed by RNA RT-
PCR [13] using the following primer set: 5′ GATGACTTCCTT
TCTCGCTGAGGT 3′ and 5′ CTTCCCAGGAAGAGAGGCGA 3′.
Lentivirus Infection
Lentivirus transduction was performed as described previously [14].
Briefly, shRNA-Ccl2 shRNA-1 (5′GAATGTGAAGTTGACCCGTAA
3′), shRNA-Ccl2 shRNA-2 (5′GAATGGGTCCAGACATACATT3′),
and LacZ shRNA (5′ CCGTCATAGCGATAACGAGTT 3′) in the
pLKpuro plasmid were individually co-transfected with pMDLg/pRRE,
pRSV-REV and pCMV-VSV-G plasmids into HEK293T cells using the
FuGENEHD transfection reagent (Roche). f-BRAF-expressing
neurospheres (Ad5-Cre-infected KIAA1549:BRAF NSCs) were
dissociated into single cells by trypsinization, plated on poly-D-lysine-
and fibronectin-coated plates, and transduced with virus-containing
supernatants from the transduced HEK293T cells. Cells with stable
expression of Ccl2 and LacZ siRNA were selected using 0.25 μg/ml
puromycin. Transfection was confirmed by RT-PCR.
Intracranial Injections
Four-week-old wild-type C57/BL6 or Ccr2-deficient male mice were
anesthetized with an intraperitoneal (i.p.) injection of 100 mg/kg ketamine
and 6mg/kg xylazine. NSCs (5×105 cells) in 2 μl of PBS were injected into
the cerebellum using a Hamilton syringe and a stereotaxic apparatus
(coordinates = posterior 5.8 mm from the bregma, lateral 0.7 mm [right],
and depth 2.5mm from duramater).Mice were euthanized 6months later.
Immunohistochemistry
Paraffin sections were processed as previously reported [12] prior to
staining with appropriate primary antibodies (Supplemental Table 1).
Biotinylated secondary antibodies (Vector Laboratories) were used in
combination with Vectastain Elite ABC development and hematox-
ylin counterstaining.
Real-Time qRT-PCR
RNA was purified using the RNeasy Plus Mini Kit (Qiagen) prior to
treatment with (10 U) DNase I recombinase (Roche). The DNase was
then heat inactivated with EDTA chelation. RNA was reverse
transcribed into cDNA using the Omniscript RT kit (Qiagen).
Real-time qRT-PCR was performed as previously described [15]
using mouse-or human-specific primers (Supplemental Table 2).
For each gene, the ΔΔCT values were calculated, where H3f3a
(or H3F3A for human specimens) was used as an internal control.
Chemokines and Receptors RT2 profiler PCR array (PAMM-022Z;
Qiagen) analyses were performed according to the manufacturer's
recommendations.
Human Pilocytic Astrocytoma (PA) Cell Lines
Following Institutional Review Board approval (Protocol
#2016–014), tumor specimens were procured by C.K. and C.A.W.
during standard surgical resection by R.M.L. at Dayton Children's
Hospital, after necessary tissues were submitted for pathologic
diagnosis. Parental consent and, when applicable, patient assent was
obtained prior to collection. Fresh tissues for culture were prepared as 50
to 200-mg specimens, placed directly into culturemedium consisting of
Dulbecco's Minimum Essential Media with F12, 10% heat-inactivated
fetal bovine serum (FBS), and 100 μg/ml Primocin™ (Invivogen, Inc.),
and transported on wet ice to a sterile hood. Tumors were minced
and digested with trypsin and collagenase IV at 37 ° C for 30minutes,
and then inactivated with FBS. Cells were then centrifuged at
1000 rpm for 3 minutes, resuspended in culture medium, and added
to 100-mm tissue culture plates. Adherent cells were passaged when
70–80% confluent. Prior to transport, cells were removed with
trypsin digestion, followed by FBS inactivation, and centrifuged at
1000 rpm for 3 minutes. Cell pellets were shipped on dry ice to
Washington University for further processing and analysis. Clinical
and BRAF mutation information is included in Supplemental
Table S3. Normal human astrocytes (NHA cells; ScienCell Research
Laboratories, Inc.) were grown according to the manufacturer's
recommendations.
Western Blotting
Cell pellets were lysed in RIPA lysis buffer supplemented with
proteinase and phosphatase inhibitors. Protein samples were separated
by SDS-PAGE, and then transferred onto Immobilon membranes.
Membranes were blocked in Tris-buffered saline 0.1% Tween 20
(TBST) with 5% non-fat dry milk, and incubated with the primary
antibodies listed in Supplemental Table 1. Antibodies were diluted in
blocking buffer or 5% BSA TBST overnight at 4°C, and horseradish
peroxidase conjugated secondary antibodies were added for 1 hour at
room temperature prior to chemiluminescence development.
ELISA
Conditioned medium (CM), was collected from control and f-
BRAF-expressing NSCs, and the levels of CCL2 determined using the
Mouse/Rat or Human CCL2/JE/MCP-1 Quantikine ELISA kit
(R&D). The number of cells were counted for each condition and
used for normalization.
Results and Discussion
Since increased monocyte (microglia and macrophage) infiltration is
associated with f-BRAF-expressing pilocytic astrocytomas in children
[7,9,16] and f-BRAF-expressing NSC glioma-like lesion formation in
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Figure 1. f-BRAF-expressing cerebellar NSCs produce Ccl2. (A) GFAP-immunoreactive cells are present at the injection sites of control and f-BRAF
NSC-injectedwild-typemice. Injectedsiteswith tumorsalsocontainGFP-positive f-BRAF-expressingcells. Increased Iba1+ cells were detected in
f-BRAF-induced lesions. (B) f-BRAF transgene expressionwas confirmed byRT-PCR inKIAA1549:BRAFcerebellarNSCs infectedwithAd5-Cre.
f-BRAF-expressingcerebellarNSCshave increasedproliferation relative tocontrols. (C) IncreasedERKandS6phosphorylationwasobserved following
f-BRAF expression in cerebellar NSCs. (D) Chemokine antibody array revealed increased Cxcl10, Ccl2, Cxcl1 and Cxcl5 expression in the culture
medium (CM) of f-BRAF-expressing cerebellar NSCs relative to controls. Boxes denote the increased candidate chemokines. (E) Quantitative analysis
of increased chemokines in f-BRAF-expressing cerebellar NSCs using a chemokine PCR array. The mRNA level fold change (FC) for the indicated
chemokines are shown in the Table. (F)Ccl2 knockdownusing two independently generatedCcl2 shRNAsdemonstratesdecreased Ccl2mRNA in
f-BRAF-expressing cerebellar NSCs (left). Cxcl10mRNA levels were decreased in Ccl2 knockdown f-BRAF-expressing cerebellar NSCs (right).
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mice [5], we sought to determine whether f-BRAF induces chemokine
expression to recruit Iba1+ monocytes to the tumor site (Figure 1A). To
induce f-BRAF expression in the presumed cells of origin for cerebellar
low-grade glioma, primary cerebellar NSCs were generated from PN2
conditional knock-in KIAA1549:BRAF (f-BRAF) mice [11]. Following
adenovirus infection, f-BRAF expression was only induced in Ad5-Cre-
infected NSCs, but not in control Ad5-LacZ-infected cerebellar NSCs
(Figure 1B). Similar results were also obtained following infection with a
retrovirus containing the KIAA1549:BRAF transgene (data not shown),
and these two approaches were used interchangeably. Similar to our
previous studies using thesemethods [5,11], f-BRAF-expressing cerebellar
NSCs exhibited elevated ERK activation (ERKThr202/Tyr204 phosphor-
ylation) and increased phosphorylation (activation) of ribosomal S6
protein (Ser240/244) (Figure 1C). In addition, f-BRAF-expressing
cerebellum NSCs proliferated faster than infected controls (Figure 1B).
Consistent with previous reports [5,11,17–19], f-BRAF induces low-
grade glioma formation and growth through increased activation of B-
RAF downstream effectors, including MEK/ERK and mTOR.
To identify potential chemokines produced by f-BRAF-expressing
cerebellar NSCs, we employed a commercial chemokine protein
array. Since chemokines are typically secreted paracrine factors, we
used conditioned medium (CM) from f-BRAF-expressing and wild
type cerebellar (control) NSCs (Figure 1D). In addition, we analyzed
chemokine mRNA expression using a commercial RT profiler PCR
array (Figure 1E). Using both methods, four potential chemokines
were identified (Cxcl1, Cxcl5, Cxcl10, Ccl2) at the protein and
mRNA levels. However, only Ccl2 and Cxcl1 exhibited N3-fold
increases. For this reason, we focused on Ccl2 and Cxcl1.
First, we sought to determine whether Ccl2 regulated Cxcl1
expression, and therefore functioned as the key chemokine to regulate
monocyte attraction. By using two independently generated Ccl2
shRNA constructs, we found that Ccl2 knockdown reduced Cxcl1
expression in f-BRAF-expressing cerebellar NSCs (Figure 1F), thus
positioning Ccl2 as the master regulator worthy of further investigation.
Second, we leveraged the online NCBI GEO database, which
contains two separate gene expression profiles from human PAs and
normal brain samples (GSE42656 and GSE44971). GSE42656
contains 14 PAs and 4 fetal brain controls, whereas GSE44971 has
35 cerebellar PAs and 9 normal cerebellum samples. In both datasets,
CCL2 levels were elevated in the PAs relative to their non-neoplastic
counterparts (Figure 2A). In addition, since the fusion BRAF
rearrangement is a genomic hallmark of optic pathway and cerebellar
PAs [3,20], we compared cerebellar PAs to non-neoplastic cerebellar
tissue in the GSE44971 dataset, and similarly observed increasedCCL2
expression in the tumors (Figure 2B). Moreover, we obtained three
short-term primary human PA cell lines established from fresh surgical
specimens, and analyzed them for CCL2 mRNA expression. CCL2
mRNA was increased in all 3 PA cell lines relative to normal human
astrocytes (Figure 2C), demonstrating that the tumor cells produce
CCL2. Third, Ccl2 expression was increased four-fold in indepen-
dently-isolated f-BRAF-expressing cerebellar NSCs at the protein level
(ELISA) (Figure 2D), whereas in cortical NSCs and cerebellar
astrocytes, which do not increase their proliferation in response to f-
BRAF, did not (Figure 2E). In this regard, previous studies have
revealed that f-BRAF expression has both tissue- and cell-type specific
effects: Whereas f-BRAF induces mTOR activation and increased cell
growth in brainstem and cerebellar NSCs, no increase in mTOR
activation or cell proliferation was observed when f-BRAFwas expressed
in cerebellar astrocytes or cortical NSCs [5,13]. These latter results
indicate that the patterning of gliomagenesis is partly dictated by the
specific cell of origin (cell type and brain region) [13,14].
Taken together, based on these convergingmouse and human data, we
sought to focus on Ccl2 as an f-BRAF-regulated chemokine potentially
important for recruiting microglia to establish a permissive tumor
microenvironment. CCL2 has been previously implicated in tumorigen-
esis and metastasis in several other solid tumor types [21,22], including
high-grade glioma [23,24]. As such, malignant glioma cells elaborate
chemoattractants, including CCL2, that promote the directional
migration of macrophages and microglia to the developing tumor bed
[25–29]. In addition, a correlation between glioma grade and tumor
microglia/macrophage content has been demonstrated [30]. However,
the role of CCL2 in PA tumorigenesis has not been investigated.
To determine whether Ccl2 is regulated by BRAF-mediated ERK
activation, control and f-BRAF-expressing cerebellar NSCs were treated
with two different MEK inhibitors, PD0325901 (PD901) and
Trametinib, each resulting in decreased ERK activation (Thr202/Tyr204
phosphorylation; Figure 3A). Following either PD901 or Trametinib
treatment,Ccl2mRNA level and protein levels were reduced (Figure 3,B
and C), indicating that Ccl2 is regulated by the BRAF-MEK–ERK
signaling pathway, consistent with the known function of f-BRAF in
MEK/ERK activation [5,11,17–19].
Ccl2 gene expression is transcriptionally controlled at the promoter
level by several different transcriptional regulators, including NFκB, C/
EBP1, AP-1 and SP-1 [31]. Since NFκB is an important transcription
factor for CCL2 regulation in glial cells [32], we sought to determine
whether BRAF-MEK–ERK mediates Ccl2 induction through NFκB
activation. NFκB activation is partly regulated through IκB phosphor-
ylation, where the inactive cytosolic form of NFκB becomes associated
with IκBα. Following IκBα phosphorylation, the NFκB heterodimer
dissociates from IκBα and enters the nucleus in its active form. As
shown in Figure 3D, IκBα phosphorylation (NFκB activation) is
increased in f-BRAF-expressing cerebellar NSCs, and MEK inhibition
leads to reduced IκBα phosphorylation (Ser
32) levels. Lastly, to
demonstrate that NFκB activation is responsible for f-BRAF-mediated
Ccl2 induction, f-BRAF-expressing cerebellar NSCs were treated with
TPCA-1, a selective inhibitor of IκBα kinase that inhibits NF-κB
nuclear localization. f-BRAF-expressing NSCs treated with TPCA-1
showed reduced IκBα phosphorylation (Ser
32) level and decreased Ccl2
mRNA expression (Figure 3E), thus establishing that f-BRAF regulates
Ccl2 expression in aMEK/NFκB-dependent manner. The finding that
Ccl2 induction following f-BRAF expression in cerebellar NSCs
involves MEK/ERK-dependent IκB kinase and NFκB activation is
consistent with previous reports in other cell types (macrophages),
where lipopolysaccharide (LPS)-induced NFκB activation is dependent
upon ERK activation through the prevention of activate IκB kinase
degradation [33]. In addition, MEK/ERK signaling pathway activation
is similarly important for TNFα-induced CCL2 expression in human
proximal tubular epithelial cells [34].
Since Ccl2 could potentially function in an autocrine manner, as
previously reported for CXCL12 and CCL5 [35,36], we sought to
determine whether Ccl2 could promote f-BRAF-expressing cerebellar
NSC growth. Because Ccl2 can act through its receptors, Ccr2 and
Ccr4, to increase NSC growth, we first examined Ccl2 receptor
expression, and found that cerebellar NSCs express only the Ccr4
receptor (Figure 4A). Second, we added recombinant mouse Ccl2
(200 ng /ml) to control and f-BRAF-expressing cerebellar NSCs, but
observed no significant increase in proliferation (Figure 4B). Third,
we assessed the effect of Ccl2 silencing on f-BRAF-expressing NSC
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proliferation. shRNA-mediated Ccl2 knockdown using two indepen-
dently derived shRNA constructs had no effect on f-BRAF-expressing
cerebellar NSC proliferation (Figure 4C). Taken together, Ccl2 does not
increase f-BRAF-expressing cerebellar NSC growth, suggesting that its
primary effect is paracrine, as previously shown for human malignant
glioma cell lines [37].
To determine whether CCL2 was responsible for microglia
infiltration and glioma-like lesion formation in vivo, f-BRAF-
A
B
C
D E
Figure 2. Human andmouse low-grade glioma cells produce CCL2. (A)Microarray analysis ofCCL2,CXCL1,CXCL5 andCXCL10mRNA levels
in two different human PA datasets (GSE42565 and GSE44971), comparing PAs and control non-neoplastic brain samples, displayed as fold
changeswith p-values. (B) Microarray analysis containing only cerebellar PA tumors and non-neoplastic cerebellar tissue (GSE44971 dataset)
reveals increased CCL2 expression in the tumors. (C) Increased CCL2 mRNA expression is observed in three primary human PA tumors
relative to normal human astrocyte (NHA) controls. Data are expressed as fold changes relative to the normal human astrocytes. (D) f-BRAF-
expressing cerebellar NSCs express more Ccl2 protein as measured by ELISA. (E) Cortex NSCs (left) and cerebellum astrocytes (right)
expressing f-BRAF show no increase in Ccl2mRNA expression. Error bars denote mean ± SD. (*) P b .05, (***) P b .001.
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Figure 3. Increased Ccl2 by f-BRAF is mediated by MEK–ERK-NFκB activation. (A) Increased ERK phosphorylation in f-BRAF-expressing
cerebellar NSCs was attenuated following treatment with 10 nM PD0325901 (PD901; top) or 50 nM Trametinib (Tra; bottom). α-tubulin is
an internal protein loading control. Veh, Vehicle. (B) Increased Ccl2 mRNA levels in f-BRAF-expressing cerebellar NSCs were reduced to
control cells levels following treatment with PD901 (top) or Trametinib (Tra; bottom). (C) Increased Ccl2 protein levels in f-BRAF-
expressing cerebellar NSCs were reduced to control levels following PD901 or Trametinib treatment as measured by ELISA. (D) Phospho-
IκB (Ser32) was decreased in f-BRAF-expressing cerebellar NSCs following PD901 or Tra treatment. (E) The increased phospho-IκBα
(Ser32) in f-BRAF-expressing cerebellar NSCs was decreased following treatment with 500 nm TPCA-1. Increased Ccl2 mRNA level in f-
BRAF-expressing cerebellar NSCs was reduced to control cell levels following TPCA-1 treatment.
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expressing cerebellar NSCs were injected into the cerebella of 4-week-
old wild type and Ccr2-deficient mice (Ccr2RFP/Ccr2RFP mice).
Using this method, low-grade glioma-like form between 3 and 6
months after the injection of f-BRAF-expressing cerebellar NSCs. In
striking contrast, no tumors form in mice engrafted with wild type
(control) cerebellar NSCs. However, in both cases, the injection site
exhibited increased glial fibrillary acid protein (GFAP) immunoreac-
tivity, thus enabling the identification of the site of injection in each
mouse (Figure 5). Since f-BRAF-expressing NSCs express green
fluorescent protein (GFP), GFP+ cells were only identified at the
injection sites of f-BRAF NSCs-transplanted mice. Consistent with
our previous study, at 6 months post-injection, f-BRAF-expressing
NSC-engrafted wild type mice (n = 5) had increased numbers of
proliferating (Ki67+) cells and increased microglia (Iba1+ cells)
infiltration relative to control NSC-injected wild type mice (n = 5)
(Figure 5). In striking contrast, Ccr2-deficient mice bearing f-BRAF-
expressing NSCs (n = 5) showed reduced numbers of proliferating
cells and microglia infiltration relative to wild-type mice. Given the
absence of an autocrine effect, these results indicate that Ccl2
establishes a supportive microenvironment for gliomagenesis through
Ccr2-mediated microglia recruitment.
The importance of microglia and macrophages to glioma
formation, growth and invasion is further underscored by several
studies in which pharmacologic or genetic silencing of microglia/
macrophage function attenuates malignant glioma growth
[27,38–40]. Moreover, in Nf1 mouse models of low-grade glioma,
A
B
C
Figure 4. Ccl2 does not function in an autocrine manner to increase cerebellar NSC growth. (A) Ccr4, but not Ccr2, mRNAwas detected in
cerebellar NSCs. (B) Recombinant Ccl2 protein did not increase control or f f-BRAF-expressing cerebellar NSC proliferation. (C) Ccl2
knockdown in f-BRAF-expressing cerebellar NSCs had no effect on cell proliferation.
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we have previously shown that microglia are critical for glioma
formation and growth [6,8,41] through the elaboration of key
chemokines [35], specifically Ccl5 [42].
While the mechanism underlying microglia support of KIAA1549:
BRAF-associated low-grade glioma growth remains to be elucidated, we
have excluded numerous chemokines previously implicated in Nf1
mouse low-grade glioma pathogenesis, including Ccl5 and Cxcl12 (data
not shown). Future investigations will be required to identify the
responsive microglia-produced growth factors that support sporadic
low-grade glioma growth. Nonetheless, in the current study, we
establish that Ccl2 is the major chemokine produced by KIAA1549:
BRAF-expressing NSCs important for low-grade glioma-like lesion
formation in mice. In addition to demonstrating the molecular
mechanism responsible for MEK-driven Ccl2 transcription, we
demonstrate that Ccr2 is required for both microglia infiltration and
low-grade glioma-like lesion formation in vivo. Collectively, these
findings reveal how the frequently reported PA genetic alteration,
KIAA1549:BRAF creates a permissive low-grade glioma microenviron-
ment in a paracrine fashion through the Ccl2/Ccr2 axis.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.11.007.
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